FIL Ltd Grows Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

FIL Ltd boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 737.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 159,671 shares of the company’s stock after acquiring an additional 140,608 shares during the period. FIL Ltd owned 0.16% of Intellia Therapeutics worth $1,862,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Whipplewood Advisors LLC purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at about $40,000. Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics in the 4th quarter worth approximately $43,000. Jones Financial Companies Lllp increased its stake in Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after acquiring an additional 2,280 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Intellia Therapeutics by 80.6% during the 4th quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock worth $60,000 after acquiring an additional 2,299 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Intellia Therapeutics by 62.4% during the 4th quarter. KBC Group NV now owns 6,093 shares of the company’s stock valued at $71,000 after acquiring an additional 2,340 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NTLA. Chardan Capital decreased their price target on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Truist Financial dropped their price target on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. BMO Capital Markets decreased their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Wedbush reiterated a “neutral” rating and issued a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Finally, Wells Fargo & Company decreased their price target on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Stock Up 9.5 %

Shares of NASDAQ:NTLA opened at $7.41 on Monday. The business’s 50 day moving average is $9.15 and its 200 day moving average is $12.53. The stock has a market cap of $767.06 million, a P/E ratio of -1.36 and a beta of 2.23. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.